The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials

Pharmacol Ther. 2023 Jan:241:108333. doi: 10.1016/j.pharmthera.2022.108333. Epub 2022 Dec 14.

Abstract

Although in the last few decades we have witnessed the rapid development of treatments for non-small cell lung cancer (NSCLC), it still remains the leading cause of cancer-related death. Increasing efforts have been devoted to exploring potential biomarkers and molecular targets for NSCLC. Foxp3, a transcription factor that was discovered as a master regulator of regulatory T cells (Tregs), has been found to express abnormally in tumoral cells including lung cancer cells. In recent years, increasing evidence have surfaced, revealing the carcinogenic effect of FOXP3 in lung cancer. In this review, we analyzed and summarized the function of FOXP3, its regulation and therapeutic potentials in NSCLC, with a hope to facilitate the development of novel treatments for NSCLC.

Keywords: FOXP3; NSCLC; Oncogene; Therapeutic target.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / metabolism
  • Forkhead Transcription Factors
  • Humans
  • Lung / metabolism
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / metabolism
  • T-Lymphocytes, Regulatory

Substances

  • Forkhead Transcription Factors
  • FOXP3 protein, human